

ASX ANNOUNCEMENT

Appendix 3B - Issue and Lapse of Options

For Immediate Release: 5 June 2018

Sydney, Australia – Simavita Limited (**Simavita** or the **Company**) (ASX: SVA) advises that the attached Appendix 3B advises of the issue of unlisted options and the lapse of unlisted options due to the resignation of certain employees.

For further information, please check our website (www.simavita.com) or contact:

Ms Peta Jurd

E: <u>pjurd@simavita.com</u> T: +61 2 8405 6361

About Simavita

Simavita (ASX: SVA) develops and markets advanced systems associated with smart, wearable and disposable sensors for the global diaper manufacturing industry and also for the aged and disabled care markets. This industry currently generates approximately USD 21bn in annual revenues.

Simavita offers an extremely low cost sensor platform technology for everyday use in all adult and infant diapers. AlertPLUS™ is incorporated into the diaper manufacturing process and connects to your smart device via an App. The platform is ready for partnering with major international diaper manufacturers.

Simavita's technology portfolio also includes AssessPLUS™, an easy to use tablet based product for the assessment of incontinence which delivers a personalised, evidence base incontinence care plan.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. www.simavita.com

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced\ 01/07/96\ \ Origin:\ Appendix\ 5\ \ Amended\ 01/07/98,\ 01/09/99,\ 01/07/00,\ 30/09/01,\ 11/03/02,\ 01/01/03,\ 24/10/05,\ 01/08/12,\ 04/03/13,\ 01/08/12,\ 04/03/13,\ 01/08/12,\ 01/08/1$

Sima	vita Limited	
ARBN		
165 8	31 309	
We (t	he entity) give ASX the following i	nformation.
	t 1 - All issues ust complete the relevant sections (attach sh	neets if there is not enough space).
1	⁺ Class of ⁺ securities issued or to be issued	Unlisted Options over CHESS Depositary Interests (CDIs)
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	50,000
3	Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due	Unlisted Options exercisable at AUD\$0.05 on or before 4 June 2025, vesting on satisfaction of agreed performance conditions.

conversion)

dates for payment; if


+convertible securities, the conversion price and dates for

Name of entity

⁺ See chapter 19 for defined terms.

4	Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?	Not applicable
	If the additional +securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issue of options to employees in accordance with Stock Option Plan.
6a	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the ⁺ securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	15 December 2017
6c	Number of ⁺ securities issued without security holder approval under rule 7.1	Not Applicable
6d	Number of ⁺ securities issued with security holder approval under rule 7.1A	Not Applicable

⁺ See chapter 19 for defined terms.



⁺ See chapter 19 for defined terms.

Number and +class of all
+securities quoted on ASX
(including the +securities in section 2 if applicable)

Number	+Class
309,899,594	CDIs (listed on ASX)*

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

	Number	+Class
	Options	
	554,000	Options at \$0.70, expiry 31 August 2018
l	300,000	Options at \$0.68, expiry 31 March 2019
	250,000	Options at \$0.50, expiry 18 September 2018
	12,559,844	Options at \$0.05, expiry 23 June 2023
	4,500,000	Options at \$0.06, expiry 13 October 2023
	850,000	Options at \$0.12, expiry 13 October 2023
	250,000	Options at \$0.05, expiry 13 December 2023
	2,500,000	Options at \$0.065, expiry 5 June 2019
	2,000,000	Options at \$0.05, expiry 28 June 2024
	3,080,000	Options at \$0.05, expiry 14 February 2025
	50,000	Options at \$0.05, expiry 4 June 2025
	Convertible Note 4	The Convertible Notes have a total value of \$1,350,000, carry an interest rate of 10% per annum and mature on the earlier of 31 July 2018 or Company's next capital raising. The Convertible Notes will convert on the basis of \$0.04 per CDI or a lesser amount if the conversion is triggered by a capital raising at a price less than \$0.04 per CDI.
	3	The Convertible Notes have a face value of \$1,400,000 and carry an interest rate of 10% per annum.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			
1 1/ /1			

⁺ See chapter 19 for defined terms.

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the +securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A

⁺ See chapter 19 for defined terms.

23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by	N/A
	sale through a broker)?	
33	⁺ Issue date	N/A

⁺ See chapter 19 for defined terms.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type of ⁺ securities (tick one)	
(a)		+Securities described in Part 1
(b)		All other ⁺ securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the

+securities held by those holders

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of +securities for which +quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
40	Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?	N/A	
	If the additional +securities do not		
	rank equally, please state:		
	• the date from which they do		
	• the extent to which they		
	participate for the next dividend, (in the case of a trust, distribution) or interest payment		
	• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another +security, clearly identify that other +security)		
		Number	+Class
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)	N/A	N/A

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before [†]quotation of the [†]securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Company Secretary

Pfend

Date: 5 June 2018

Print name: **Peta Jurd**

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	309,899,594	
Add the following:		
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2	-	
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	0	
"A"	309,899,594	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
Multiply "A" by 0.15	46,484,939	
Step 3: Calculate "C", the amount of place already been used	ement capacity under rule 7.1 that has	
 <i>Insert</i> number of ⁺equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued: Under an exception in rule 7.2 Under rule 7.1A 	0	
• With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	0	
Step 4: Subtract "C" from ["A" x "B"] capacity under rule 7.1	to calculate remaining placement	
"A" x 0.15 Note: number must be same as shown in Step 2	46,484,939	
Subtract "C"	0	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	46,484,939 [Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2:

Rule 7.1A – Additional placen	nent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in Step	309,899,594	
1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	30,989,959	
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	0	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
ine items "E"	0	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	30,989,959
Note: number must be same as shown in Step 2	
Subtract "E"	0
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	30,989,959
	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.